OrganiGram (OGI) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 saw four consecutive quarters of expanding net revenue, rising adjusted gross margins, and 55% full-year adjusted EBITDA growth year-over-year.

• Achieved #1 market share in Canada post-Motif acquisition, with leading positions in vapes, pre-rolls, hash, concentrates, and milled flower.

• Strategic CAD 124.6 million investment from BAT and the establishment of the CAD 83 million Jupiter Fund enabled international expansion, including a $21M stake in Germany's Sanity Group and U.S. exposure via OBX and Phylos.

• Motif acquisition post-year-end made the company the top Canadian licensed producer by market share, adding CAD 86 million in run rate net revenue.

• Closed two tranches of a $124.6M follow-on investment from BAT, with the final tranche expected in February 2025.

Financial highlights

• Q4 net revenue grew 10% sequentially and 22% year-over-year to $44.7 million.

• Adjusted gross margin reached 37% in Q4, up from 20% in Q4 last year; full-year adjusted gross margin was 34%, up from 25%.

• Q4 adjusted EBITDA was $5.9 million, up 69% sequentially and 10,003% year-over-year; full-year adjusted EBITDA rose 55% to $8.4 million.

• Net loss for Q4 was $5.4 million, a significant improvement from $26.6 million loss in the prior year period; full-year net loss narrowed to $45.4 million from $247.0 million.

• Cash and short-term investments at year-end were $133.4 million, with a pro-forma cash position of ~$120 million post-Motif and BAT investment.

Outlook and guidance

• Fiscal 2025 expected to deliver higher adjusted EBITDA and positive cash flow from operations, with gross margins anticipated to stabilize above 35% and continued cost synergies from Motif acquisition.

• EU GMP certification expected in early 2025, enabling higher-margin international sales and supporting international revenue growth.

• Final $41.5M BAT investment tranche expected to close in February 2025, further enhancing liquidity.

• Targeting 20% of cannabis harvests from seeds in Fiscal 2025 to reduce cultivation costs.

• Canadian cannabis market projected to grow 4% in 2025; company aims to outpace market growth and gain share from smaller players.